Key result
Contemporary radiation therapy for Hodgkin lymphoma minimizes toxicity and preserves disease control through customized regimens.
Why the study?
Refinement of radiation delivery in combined modality therapy for Hodgkin lymphoma is needed to minimize toxicity while preserving disease control.
This review highlights the evolution of radiation therapy in combined modality treatment for Hodgkin lymphoma to minimize toxicity while preserving disease control.
Supports minimizing radiation exposure in Hodgkin lymphoma; leaves open optimal integration with novel systemic agents.
The advent of effective combination chemotherapy markedly changed the management of Hodgkin lymphoma, establishing combined modality therapy as the standard of care for most patients with this disease. In response, significant interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized while still preserving disease control. An understanding of the way in which radiation treatment fields, prescription dose, and advanced technology have evolved to accomplish these goals is critical. Moreover, fluency in the clinical literature exploring contemporary questions, such as the omission of radiation and response-based treatment, is equally important. Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ability to better customize treatment regimens to individual patients.
No takes yet. Share an insight, caveat, or question.
Narang et al. (2015) conducted a review in Hodgkin lymphoma. Contemporary Radiation Therapy in Combined Modality Therapy was evaluated. Contemporary radiation therapy in combined modality treatment for Hodgkin lymphoma has evolved to minimize toxicity while preserving disease control, highlighting the importance of customized regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: